{"createdAt":"8/2/2020, 2:37:36 PM","timestamp":1596393456359,"Company ID number":"652","DMX_ISSUER_NAME":"YUNNAN BAIYAO GROUP CO., LTD","DMX_ISSUER_ID":"IID000000002190202","Country of Classification":"CHINA","name":"Yunnan Baiyao Group Co Ltd ","code":"000538","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"云南白药集团股份有限公司_王明辉","group":"board","name":"王明辉","title":"董事长,董事","isMale":true,"age":"58","degree":"硕士","salary":"31.21万","stockAmount":"-","description":"王明辉,男,生于1962年4月,研究生,高级经济师。历任宾川县医药公司主持工作副经理,昆明制药厂计划经营科副科长,昆明制药厂劳动服务公司经理,昆明贝克诺顿制药有限公司副总经理,昆明八达实业总公司董事长、总经理,昆明制药股份有限公司董事、副总裁,云南医药集团有限公司总经理,云南云药有限公司董事长、总经理,云南白药集团股份有限公司董事长、总裁。现任云南白药集团股份有限公司董事长、云南白药控股有限公司总经理。于2019年9月12日获委任为万隆控股集团有限公司执行董事及董事会主席。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_陈发树","group":"board","name":"陈发树","title":"联席董事长,董事","isMale":true,"age":"60","degree":"","salary":"0.00","stockAmount":"894.8万","description":"陈发树,男,生于1960年10月。新华都集团的主要出资人和创办人,现任云南白药集团股份有限公司董事长,新华都咨询法定代表人及执行董事,新华都房地产开发有限公司董事长,新华都集团(中国香港)董事、法定代表人,福建省发树慈善基金会理事长,云南白药控股有限公司法人代表、董事长。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_汪戎","group":"board","name":"汪戎","title":"副董事长,董事","isMale":true,"age":"66","degree":"博士","salary":"22.10万","stockAmount":"-","description":"汪戎,男,生于1954年10月,博士研究生学历,云南财经大学教授,管理学博士生导师。历任云南大学经济学院副院长、副校长;云南财经大学校长、党委书记;云南财经大学印度洋中心教授、首席专家;泰国正大商学院博士生导师;全国MBA教学指导委员会委员,教育部经济学教学指导委员会委员;云南铜业独立董事、云天化和云南建工外部董事。现任云南白药控股有限公司董事,副董事长。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_杨昌红","group":"board","name":"杨昌红","title":"董事","isMale":true,"age":"57","degree":"本科","salary":"22.21万","stockAmount":"-","description":"杨昌红,男,生于1963年7月,大学本科,高级工程师。历任大理师专讲师、云南省分析测试中心高级工程师、云南白药集团股份有限公司企业发展部部长、总裁(总经理)助理、董事、常务副总裁。现任云南白药集团股份有限公司执行董事、云南白药控股有限公司党委副书记兼副总经理。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_李双友","group":"board","name":"李双友","title":"董事","isMale":true,"age":"52","degree":"本科","salary":"0.00","stockAmount":"-","description":"李双友先生:1968年12月出生,本科,高级会计师。李双友先生曾任玉溪卷烟厂计财统计科科员,云南红塔集团有限公司计划财务科科长、副总经理、党委书记、董事;现任云南合和(集团)股份有限公司副总经理,兼任云南红塔银行股份有限公司董事、云南白药集团股份有限公司董事、昆药集团股份有限公司副董事长、云南旅游股份有限公司董事、华泰保险集团股份有限公司董事、红塔创新投资股份有限公司董事长、云南昆玉高速公路开发有限公司董事、云南安晋高速公路开发有限公司董事、云南红塔滇西水泥股份有限公司董事长、华能澜沧江水电股份有限公司副董事长、一汽红塔云南汽车制造有限公司董事、中维资本控股股份有限公司董事。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_陈焱辉","group":"board","name":"陈焱辉","title":"董事","isMale":true,"age":"34","degree":"本科","salary":"18.69万","stockAmount":"12.67万","description":"陈焱辉,男,生于1986年4月,大学本科。现任云南白药集团股份有限公司董事,兼任新华都集团(上海)投资有限公司、保亭半山半岛雨林地产有限公司、昆明德和罐头食品有限责任公司法人代表、董事长。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_纳鹏杰","group":"board","name":"纳鹏杰","title":"董事","isMale":true,"age":"55","degree":"博士","salary":"18.67万","stockAmount":"-","description":"纳鹏杰,男,生于1965年1月。云南财经大学教授、博导,云南省中青年学术与技术带头人。西南财经大学博士、中山大学博士后。2000年至2014年历任云南财贸学院投资研究所副所长,云南财经大学投资研究所所长、MBA教育学院院长及商学院党委书记。历任锡业股份、景谷林业、云南盐化、罗平锌电、云南地矿、滇西水泥等公司独立董事,现任云南白药控股有限公司董事,贵研铂业股份有限公司独立董事,云南省工业投资控股集团有限责任公司外部董事,昆明自来水集团有限公司外部董事。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_张永良","group":"board","name":"张永良","title":"独立董事","isMale":true,"age":"52","degree":"硕士","salary":"8.570万","stockAmount":"-","description":"张永良,男,生于1968年3月,法律、法学硕士,执业律师。历任中国证监会第四届、第五届上市公司并购重组审核委员会委员。现任金杜律师事务所合伙人,主要执业领域为公司并购、证券、国际投资等。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_戴扬","group":"board","name":"戴扬","title":"独立董事","isMale":true,"age":"51","degree":"本科","salary":"8.570万","stockAmount":"-","description":"戴扬,男,生于1969年1月,大学本科。历任中国证监会西藏证监局副主任科员、主任科员、综合处副处长、办公室(党办)副主任、主任及上市公司监管处处长,西藏矿业发展股份有限公司党委副书记、总经理、党委书记、董事长,永泰集团有限公司副总裁,海南海德实业股份有限公司董事长、副董事长。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_尹晓冰","group":"board","name":"尹晓冰","title":"独立董事","isMale":true,"age":"46","degree":"博士","salary":"8.570万","stockAmount":"-","description":"尹晓冰,男,汉族,1974年7月出生,经济学博士,财务学副教授,注册会计师,美国麻省理工斯隆管理学院高级访问学者。曾任云南罗平锌电股份有限公司独立董事,云南云投生态股份有限公司独立董事,云南煤业能源股份有限公司独立董事,云南白药集团股份有限公司外部董事。现任云南大学工商管理与旅游管理学院财务管理系主任,云南白药集团股份有限公司独立董事、云南铜业股份有限公司独立董事、云南锡业股份有限公司第八届董事会独立董事、审计委员会召集人、绩效薪酬委员会委员,昆明土地开发投资公司外部董事,昆明滇池水务股份有限公司外部董事,昆明经济技术开发区投资开发(集团)有限公司外部董事,昆明中北融资担保有限公司董事长,云南天枢玉衡股权投资基金管理有限公司总经理、昆明盘龙区国投公司外部董事,入选云南省国资委及昆明市国资委外部董事库、云南省人大财经委咨询专家。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_游光辉","group":"supervisoryCommittee","name":"游光辉","title":"监事会主席","isMale":true,"age":"49","degree":"本科","salary":"17.57万","stockAmount":"-","description":"游光辉,男,生于1971年12月,本科,注册管理会计师(CMA),高级企业文化师。历任福建兴业银行武夷山支行主办会计,新华都工程有限责任公司主办会计、财务科长,福建武夷山旅游发展股份有限公司监事、计划财务部副经理、经理,福建武夷山旅游发展股份公司董事、财务总监。新疆喀纳斯旅游股份有限公司监事。现任云南白药控股有限公司财务总监,云南白药集团股份有限公司监事会主席。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_钟杰","group":"supervisoryCommittee","name":"钟杰","title":"监事","isMale":true,"age":"56","degree":"硕士","salary":"17.51万","stockAmount":"-","description":"钟杰,男,生于1964年3月,硕士研究生学历,经济师。曾任云南省纺织科研所职员,云南省纺织工业局基建处科员、副主任科员,云南省经贸委技术改造处主任科员、工业二处副处长,云南省国资委产权管理处副处长,云南省国有企业监事会工作办公室第六监事会主任监事,云南解化集团有限公司副总经理,云南省工业投资控股集团公司监事会主席,云南省国资委产权管理处处长。现任云南白药控股有限公司监事会主席,云南白药集团股份有限公司监事。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_宋成立","group":"supervisoryCommittee","name":"宋成立","title":"监事","isMale":true,"age":"59","degree":"硕士","salary":"2.510万","stockAmount":"-","description":"宋成立,男,生于1961年,硕士研究生学历,高级经济师。历任中国平安财产保险上海分公司副总经理、中国平安财产保险股份有限公司副总经理,平安信托有限责任公司总经理。现任平安信托有限责任公司副董事长、总经理,云南白药集团股份有限公司董事。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_吴群","group":"supervisoryCommittee","name":"吴群","title":"监事","isMale":true,"age":"32","degree":"硕士","salary":"6700","stockAmount":"-","description":"吴群,男,生于1988年,硕士研究生学历,曾任职苏州索尼液晶显示器有限公司生产企划部担任经理助理职务,现任苏州医云健康管理有限公司CEO,江苏鱼跃医疗设备股份有限公司副董事长兼总裁,2018年至今任职北京万东医疗科技股份有限公司副董事长。","lastUpdated":"2019-08-22"},{"id":"云南白药集团股份有限公司_何映霞","group":"supervisoryCommittee","name":"何映霞","title":"职工监事","isMale":false,"age":"48","degree":"硕士","salary":"69.58万","stockAmount":"-","description":"何映霞,女,生于1972年3月,在职研究生学历,中共党员,政工师。1989年12月参加工作,历任云南白药车间工人、西南片区销售副经理、集团团委副书记、工会副主席、党群工作部部长、纪委副书记、工会主席。现任云南白药集团工会副主席、女工委主任、党群工作部部长、集团本部第一党支部书记,呈贡区第三届人大常委会委员,省总工会第十二届委员会委员、第六届女工委常委,中华全国总工会第十七届执行委员会委员、云南白药集团股份有限公司监事。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_屈华曦","group":"supervisoryCommittee","name":"屈华曦","title":"职工监事","isMale":true,"age":"54","degree":"本科","salary":"17.43万","stockAmount":"-","description":"屈华曦,男,生于1966年6月,中共党员,省委党校大学学历,讲师。1988年8月参加工作,历任思茅市孟连县委办公室干部、思茅市孟连县腊垒乡党委副书记、云南省扶贫办综合处主任科员(科长)、云南省扶贫办小额信贷处副调研员、云南省扶贫办项目管理处副处长、云南省扶贫办计划财务处处长(其间担任楚雄州武定县新农村工作总队队长,挂任县委副书记)、云南省扶贫办异地扶贫开发处处长、云南省供销合作社联合社纪检组组长、党组成员。2016年8月调至云南白药控股有限公司。现任云南白药集团股份有限公司工会主席。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_吴伟","group":"manager","name":"吴伟","title":"董事会秘书,高级副总裁,财务总监","isMale":true,"age":"50","degree":"硕士","salary":"169.5万","stockAmount":"-","description":"吴伟,男,生于1970年6月,硕士,高级会计师,取得董事会秘书资格证。历任云南白药集团股份有限公司资产财务会计、副部长、部长、董事会证券事务代表。现任云南白药集团股份有限公司财务总监兼董事会秘书。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_尹品耀","group":"manager","name":"尹品耀","title":"高级副总裁,首席运营官","isMale":true,"age":"51","degree":"本科","salary":"247.4万","stockAmount":"-","description":"尹品耀,男,生于1969年5月,大学本科,高级经济师。历任昆明制药股份有限公司财务部副经理、销售管理部经理,昆明制药药品销售有限公司财务部经理、销售服务部经理,云南白药集团医药电子商务有限公司财务部经理、云南白药集团股份有限公司资产财务部部长、副总裁兼财务总监、董事会秘书、董事。现任云南白药集团股份有限公司总经理。于2019年9月12日获委任为万隆控股集团有限公司执行董事。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_杨勇","group":"manager","name":"杨勇","title":"高级副总裁","isMale":true,"age":"56","degree":"本科","salary":"183.0万","stockAmount":"-","description":"杨勇,男,生于1964年12月,大学本科。历任云南省医药公司副总经理、云南白药集团股份有限公司董事。现任云南白药集团股份有限公司副总经理兼云南省医药有限公司总经理。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_王锦","group":"manager","name":"王锦","title":"副总经理","isMale":false,"age":"50","degree":"硕士","salary":"182.7万","stockAmount":"-","description":"王锦,女,生于1970年3月,研究生学历。历任云南白药集团医药电子商务有限公司东北分公司经理、客户服务部经理、学术推广部经理、云南白药集团商务部总经理兼学术推广部总经理、云南白药控股有限公司党委副书记。现任云南白药集团股份有限公司副总经理兼药品事业部总经理。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_秦皖民","group":"manager","name":"秦皖民","title":"副总经理","isMale":true,"age":"56","degree":"硕士","salary":"182.7万","stockAmount":"-","description":"秦皖民,男,生于1964年12月,医学硕士。历任云南白药集团医药电子商务有限公司市场部经理、副总经理,云南白药集团股份有限公司总经理助理。现任云南白药集团股份有限公司副总经理兼健康产品事业部总经理。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_李劲","group":"manager","name":"李劲","title":"技术总监","isMale":true,"age":"55","degree":"硕士","salary":"102.7万","stockAmount":"-","description":"李劲,男,生于1965年8月,工商管理硕士,高级工程师。历任副总工程师兼技术部部长、云南白药集团天紫红药业有限公司总经理。现任云南白药集团股份有限公司纪委书记、技术质量总监。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_余娟","group":"manager","name":"余娟","title":"人力资源总监","isMale":false,"age":"48","degree":"本科","salary":"123.0万","stockAmount":"-","description":"余娟,女,生于1972年1月,大学本科,高级人力资源管理师。历任云南白药集团医药电子商务有限公司行政部经理,云南白药集团股份有限公司行政人事部经理,人力资源部经理兼透皮产品事业部副总经理。现任云南白药集团股份有限公司人力资源总监。","lastUpdated":"2019-08-23"},{"id":"云南白药集团股份有限公司_朱兆云","group":"manager","name":"朱兆云","title":"研发总监","isMale":false,"age":"66","degree":"本科","salary":"100.0万","stockAmount":"-","description":"朱兆云,女,生于1954年3月,正高级工程师。历任大理州医药公司任副经理、党委委员;云南省药材公司质检科长;云南省医药工业公司副经理,党委委员,兼云南植物药厂总工,云南省医药产品监测站站长。现任云南省药物研究所所长、党委书记,云南白药集团股份有限公司研发总监。","lastUpdated":"2019-08-23"}],"companyName":"云南白药集团股份有限公司","province":"云南省","englishName":"Yunnan Baiyao Group Co., Ltd","industry":"医药生物 — 中药Ⅱ","website":"www.yunnanbaiyao.com.cn","mainBusiness":"制造和销售以云南白药系列产品和天然植物药系列产品为主的各类药品。","productsName":["云南白药","天然植物药"],"actualController":"","actualControllerSharePercentage":"","registeredCapital":"12.77亿元","employeeAmount":"8124","phone":"86-0871-66324159;86-0871-66226106","location":"云南省昆明市呈贡区云南白药街3686号","chineseDescription":"云南白药集团股份有限公司是一家主要经营化学原料药、化学药制剂、中成药、中药材、生物制品等的公司。公司产品以云南白药系列、三七系列和云南民族特色药品系列为主，共17种剂型200余个产品，产品畅销国内市场及东南亚一带，并逐渐进入日本、欧美等发达国家市场。公司是我国知名中成药生产企业之一，是云南大型工商医药企业之一，是中国中成药五十强之一。1997年被确定为云南省首批重点培育的四十家大企业大集团之一。2010中药行业品牌峰会品牌评选活动首次发布的中药行业各领域十强企业品牌榜单上，云南白药在中药企业传统品牌榜单十强中排名第一。\n    2017年9月，云南白药入选由中国医药工业信息中心发布的“2016...查看全部▼云南白药集团股份有限公司是一家主要经营化学原料药、化学药制剂、中成药、中药材、生物制品等的公司。公司产品以云南白药系列、三七系列和云南民族特色药品系列为主，共17种剂型200余个产品，产品畅销国内市场及东南亚一带，并逐渐进入日本、欧美等发达国家市场。公司是我国知名中成药生产企业之一，是云南大型工商医药企业之一，是中国中成药五十强之一。1997年被确定为云南省首批重点培育的四十家大企业大集团之一。2010中药行业品牌峰会品牌评选活动首次发布的中药行业各领域十强企业品牌榜单上，云南白药在中药企业传统品牌榜单十强中排名第一。\n    2017年9月，云南白药入选由中国医药工业信息中心发布的“2016年度中国医药工业百强企业榜”榜单。2017年，云南白药系列产品荣获2017年度中国非处方药产品综合统计排名中成药骨伤科类第一名，云南白药气雾剂荣获首届最具创新价值OTC品种十大OTC杰出创新奖，云南白药牙膏的市场占有率位居全国第二位、民族品牌第一位。2018年，公司荣获中国非处方药生产企业综合统计排名前十强，产品云南白药气雾剂、膏、创可贴、酊荣获中成药骨伤科类综合统计第一名，云南白药牙膏市场份额约18.1%，位居全国第二位。在医药商业流通领域，经过多年发展，公司全资子公司云南省医药有限公司已成为云南省销售规模最大的医药商业企业，也是云南省唯一承担云南省人民政府医药储备任务的医药企业。2019年，云南白药集团荣获由中国医药保健品进出口商会颁发的“中国中成药行业企业出口十强”称号，公司连续3年获此奖项；5月31日，国际咨询平台Interbrand发布“2019年中国最佳品牌排行榜”，云南白药品牌价值74.35亿元，排名榜单第34，位列医药板块首位。收起▲","foundedDate":"1993-11-30","goPublicDate":"1993-12-15","companyHistory":"公司前身为成立于1971年6月的云南白药厂。1993年5月3日经云南省经济体制改革委员会云体（1993）48号文批准，云南白药厂进行现代企业制度改革，成立云南白药实业股份有限公司。经中国证监会证监发审字（1993）55号文批准，公司于1993年11月首次向社会公众发行股票2,000万股（含20万内部职工股），定向发行400万股，发行后总股本8,000万股。经中国证券监督管理委员会批准，1993年12月15日公司社会公众股（Ａ股）在深圳证券交易所上市交易，内部职工股于1994年7月11日上市交易。1996年10月经临时股东大会会议讨论，公司更名为云南白药集团股份有限公司。\n　　根据2008年8月11日公司第五届董事会2008年第三次临时会议及2008年8月27日公司2008年第一次临时股东大会审议通过并经中国证券监督管理委员会证监许可〔2008〕1411号文“关于核准云南白药集团股份有限公司非公开发行股票的批复”核准，公司以非公开方式向中国平安人寿保险股份有限公司发行5,000.00万股新股，募集资金1,393,500,000.00元（含发行费用），均为现金认购。实施上述非公开发行后，公司股本由484,051,138股增至534,051,138股。\n　　依据2010年5月本公司股东大会审议通过的2009年度权益分派方案，以资本公积金向全体股东每10股转增3股，转增前本公司股本为534,051,138股，转增后总股本增至694,266,479股。\n　　2014年5月8日召开2013年度股东大会，根据会议决议和修改后的章程规定：公司股东对公司增加注册资本人民币347,133,239.00元。新增注册资本的方式为以公司现有总股本694,266,479股为基数，向全体股东每10股送红股5股。变更后，公司股本由694,266,479股增至1,041,399,718股。\n　　云南白药通过向云南白药控股有限公司的三家股东云南省国资委、新华都及江苏鱼跃发行股份的方式对白药控股实施吸收合并。云南白药为吸收合并方，白药控股为被吸收合并方。\n　　本次吸收合并于2019年6月1日完成交割，云南白药作为存续方，已承继及承接白药控股的全部资产、负债、业务、合同及其他一切权利与义务。本次交易完成后，白药控股持有的上市公司432,426,597股股份已办理股份注销手续，本次吸收合并新增注册资本为人民币236,003,599.00元，变更后上市公司的注册资本为人民币1,277,403,317.00元，本次发行新增股份为有限售条件的流通股236,003,599股，上市日为2019年7月3日，上市地点为深交所。本次交易完成后，上市公司无控股股东，无实际控制人。收起▲","shareholders":[],"englishDescription":"YUNNAN BAIYAO GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and operation of pharmaceuticals, as well as the wholesaling and retailing of purchased pharmaceuticals. The Company鈥檚 products are categorized into traditional Chinese medicine resources, Chinese and western raw medicine materials and preparations, personal care products and raw materials, with Yunnan Baiyao band-aids, Yunnan Baiyao aerosol and Yunnan Baiyao ointment as its main effective products. The Company also provides skin care products and health care products. The Company distributes its products within domestic market and to overseas markets, with domestic market as its main market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"28.35","Price to sales (ttm)":"4.60","Price to book (mrq)":"3.57","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"8.73","Lt debt to equity (mrq)":"2.37","Return on investment (ttm)":"14.83","Return on equity (ttm)":"11.19","Income statement":{"Revenue":"29,664.67","Total revenue":"29,664.67","Cost of revenue, total":"21,391.88","Gross profit":"8,272.79","Selling/general/admin. expenses, total":"5,267.35","Research & development":"164.72","Depreciation/amortization":"87.16","Interest exp.(inc.),net-operating, total":"(834.47)","Unusual expense (income)":"(1,008.63)","Other operating expenses, total":"(146.14)","Total operating expense":"24,921.88","Operating income":"4,742.79","Other, net":"(16.60)","Net income before taxes":"4,726.19","Provision for income taxes":"553.14","Net income after taxes":"4,173.05","Minority interest":"10.68","Net income before extra. items":"4,183.73","Net income":"4,183.73","Income available to com excl extraord":"4,183.73","Income available to com incl extraord":"4,183.73","Diluted net income":"4,183.73","Diluted weighted average shares":"1,277.40","Diluted eps excluding extraord items":"3.28","Dps - common stock primary issue":"3.00","Diluted normalized eps":"2.58","Gain (loss) on sale of assets":"3.99","Dilution adjustment":"0.00"},"Balance sheet":{"Cash":"0.46","Cash & equivalents":"12,993.75","Short term investments":"8,821.14","Cash and short term investments":"21,815.35","Accounts receivable - trade, net":"2,037.97","Total receivables, net":"6,676.13","Total inventory":"11,746.86","Prepaid expenses":"593.95","Other current assets, total":"3,869.08","Total current assets":"44,701.37","Property/plant/equipment, total - gross":"4,083.50","Accumulated depreciation, total":"(1,102.87)","Property/plant/equipment, total - net":"2,980.64","Goodwill, net":"33.30","Intangibles, net":"538.38","Long term investments":"877.72","Other long term assets, total":"526.64","Total assets":"49,658.05","Accounts payable":"4,590.53","Accrued expenses":"470.20","Notes payable/short term debt":"1,653.41","Current port. of  lt debt/capital leases":"0.00","Other current liabilities, total":"2,900.44","Total current liabilities":"9,614.58","Long term debt":"916.53","Total long term debt":"916.53","Total debt":"2,569.93","Deferred income tax":"133.67","Minority interest":"161.81","Other liabilities, total":"893.36","Total liabilities":"11,719.95","Common stock, total":"1,277.40","Additional paid-in capital":"17,420.06","Retained earnings (accumulated deficit)":"19,243.77","Other equity, total":"(3.14)","Total equity":"37,938.10","Total liabilities & shareholders' equity":"49,658.05","Total common shares outstanding":"1,277.40","Tangible book value per share, common eq":"29.25","Note receivable - long term":"155.41"},"Cash flow":{"Cash receipts":"33,340.46","Cash payments":"(24,786.26)","Cash taxes paid":"(1,695.74)","Changes in working capital":"(4,753.71)","Cash from operating activities":"2,104.74","Capital expenditures":"(783.28)","Other investing cash flow items, total":"14,749.55","Cash from investing activities":"13,966.26","Financing cash flow items":"(3,471.53)","Total cash dividends paid":"(2,670.52)","Issuance (retirement) of debt, net":"(3,198.63)","Cash from financing activities":"(9,340.68)","Foreign exchange effects":"6.75","Net change in cash":"6,737.08"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"109.58","52 Week High":"114.88","52 Week Low":"71.00","Pricing date":"","10 Day Average Trading Volume":"6.42","Market Capitalization":"139,977.90","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"144.44","Beta":"0.64","1 Day Price Change":"0.26","13 Week Price Return (Daily)":"21.32","26 Week Price Return (Daily)":"26.54","5 Day Price Return (Daily)":"3.62","52 Week Price Return (Daily)":"44.72","Year To Date Price Return (Daily)":"22.53","Month to Date Price Return (Daily)":"16.81","Price Relative to S&P500 (4 Week)":"-3.49","Price Relative to S&P500 (13 Week)":"-4.62","Price Relative to S&P500 (26 Week)":"-0.89","Price Relative to S&P500 (52 Week)":"-1.65","Price Relative to S&P500 (YTD)":"-6.28"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"3.28","EPS excl. Extra Items (TTM)":"3.86","EPS Normalized (Annual)":"2.58","Revenue per Share (Annual)":"23.22","Revenue per Share (TTM)":"24.98","Book Value (Per Share Annual)":"29.70","Book Value (Per Share Quarterly)":"30.67","Tangible Book Value (Per Share Annual)":"29.25","Tangible Book Value (Per Share Quarterly)":"30.24","Cash Per Share (Per Share Annual)":"17.08","Cash Per Share (Per Share Quarterly)":"18.22","Cash Flow (Per Share Annual)":"3.39","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"3.00","Dividends (Per Share TTM)":"3.00","EBITD (Per Share TTM)":"2.62","EPS Basic excl. Extra Items (Annual)":"3.28","EPS Basic excl. Extra Items (TTM)":"3.86","EPS incl. Extra Items (Annual)":"3.28","EPS incl. Extra Items (TTM)":"3.86","Free Cash Flow (Per Share TTM)":"-0.37","Dividend (Per Share 5Y)":"1.58"},"Valuation":{"P/E excl. Extra Items (Annual)":"33.46","P/E excl. Extra Items (TTM)":"28.35","P/E Normalized (Annual)":"42.51","Price to sales (Annual)":"4.72","Price to sales (TTM)":"4.60","Price to Tangible Book (Annual)":"3.75","Price to Tangible Book (Quarterly)":"3.62","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"3.69","Price to Book (Quarterly)":"3.57","P/E Basic excl. Extra Items (TTM)":"22.14","P/E excl. Extra Items High (TTM)":"34.15","P/E excl. Extra Items Low (TTM)":"19.06","P/E incl. Extra Items (TTM)":"28.35","Net Debt (Interim)":"-19,850.34","Net Debt (Annual)":"-19,245.42","Dividend Yield (5Y)":"1.91","Dividend Yield":"2.74","Current Dividend Yield (TTM)":"2.74"},"Financial Strength":{"Free Cash Flow (Annual)":"-1,349.06","Current Ratio (Annual)":"4.65","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"2.42","Payout Ratio (Annual)":"91.60","Quick Ratio (Annual)":"3.43","Total Debt/Total Equity (Annual)":"6.77","Current EV/Free Cash Flow (Annual)":"137.58","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"4.56","Long Term Debt/Equity (Quarterly)":"2.37","Quick Ratio (Quarterly)":"3.41","Total Debt/Total Equity (Quarterly)":"8.73","Free Cash Flow (TTM)":"-452.05","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"82.96"},"Margins":{"Gross Margin (Annual)":"27.89","Gross Margin (TTM)":"28.25","Net Profit Margin % (Annual)":"14.07","Net Profit Margin (TTM)":"15.15","Operating Margin (Annual)":"15.99","Operating Margin (TTM)":"17.29","Pretax Margin (TTM)":"17.24","Pretax Margin (Annual)":"15.93","Operating Margin (5Y)":"14.94","Pretax Margin (5Y)":"15.03","Free Operating Cash Flow/Revenue (5Y)":"2.49","Free Operating Cash Flow/Revenue (TTM)":"-1.49","Gross Margin (5Y)":"30.03","Net Profit Margin (5Y)":"13.27"},"Management Effectiveness":{"Return on Assets (Annual)":"8.06","Return on Equity (TTM)":"11.19","Return on Average Equity (Annual)":"10.78","Return on Average equity (TTM)":"15.42","Return on Investment (Annual)":"10.36","Return on Investment (TTM)":"14.83","Return on Average Assets (5Y)":"10.39","Return on Average Equity (5Y)":"14.82","Return on Investment (5Y)":"13.83","Asset Turnover (Annual)":"0.57","Asset Turnover (TTM)":"0.74","Inventory Turnover (Annual)":"1.88","Inventory Turnover (TTM)":"1.98","Net Income/Employee (Annual)":"515,446.20","Net Income/Employee (TTM)":"567,632.10","Receivables Turnover (Annual)":"15.24","Receivables Turnover (TTM)":"11.57","Revenue/Employee (Annual)":"3,664,115.00","Revenue/Employee (TTM)":"3,746,256.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"10.53","Revenue Growth Rate (5Y)":"9.53","EPS Growth (Quarterly YoY)":"-34.40","EPS Growth (TTM YoY)":"-3.92","EPS Growth Rate (5Y)":"6.36","Dividend Growth Rate (3Y)":"55.36","Revenue Growth (TTM YoY)":"9.93","Revenue Growth (Per Share 5Y)":"5.15","Revenue Growth Rate (3Y)":"9.80","EPS Growth Rate (3Y)":"5.32","Book Value Growth Rate (Per Share 5Y)":"22.56","Tangible Book Value Total Equity CAGR (5Y)":"27.89","Capital Spending growth rate 5 year":"34.15","EBITDA CAGR (5Y)":"1.51","EBITDA Interim CAGR (5Y)":"2.14","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"9.89","Net Profit Margin Growth Rate (5Y)":"1.17"},"Income Statement":{"Revenue (Annual)":"29,664.67","Revenue (TTM)":"30,434.58","EBITD (Annual)":"3,059.14","EBITD (TTM)":"3,197.07","Earnings Before Taxes (Annual)":"4,726.19","Earnings Before Taxes (TTM)":"5,245.95","Net Income to Common (Annual)":"4,183.73","Net Income to Common (TTM)":"4,619.51","Earnings Before Taxes Normalized (Annual)":"3,717.56","Net Income Available to Common Normalized (Annual)":"3,293.15","Diluted Normalized EPS excl. Extra Items (TTM)":"3.85"}}}